Media attention, political pressure credited with solving cardiac surgery waitlist at Waikato Hospital
A doctor works on a patient in a surgery.
Photo:
UnSplash/ JC Gellidon
Media attention and political pressure have been credited with solving the
eight-week cardiac surgery waitlist
at Waikato Hospital.
Cardiac Society of New Zealand chairperson Dr Martin Stiles said the cardiac waiting list peaked last year at 110 patients but had now reduced to only 10.
"What that has meant for us is that we are able to get through the patients much more quickly, and the patients are waiting a much shorter time."
Stiles - who was a cardiologist at Waikato Hospital but spoke in his role as chairperson - said the situation changed after 71-year-old Norm Davies went public with his story in September 2024.
Davies had
waited in hospital
for more than a month for cardiac surgery and had been told to expect at least another three-week wait.
"It was really frustrating at the time, because what we were telling patients was, 'yes you do need an operation but no we can't do it this week, or next week, or even the week after'," Stiles said.
Cardiac Society of New Zealand chairperson Dr Martin Stiles.
Photo:
Supplied: Martin Stiles
He said after the RNZ stories, senior management began to focus on the issue and political pressure was put on resolving the situation.
"There was visibility at the top of the organisation, where previously there really wasn't."
One of the problems was that up to 20 percent of planned operations were being cancelled because it wasn't clear that there would be a recovery bed available.
"Now [surgeons] get on with the operation and ICU are committed to finding them a bed, and they are able to just get through the list just much more quickly."
Stiles said he was aware of cardiac waitlist issues in other areas of the country, especially in major centres.
"What I'd say to Auckland and Wellington is that with engagement from very senior management and perhaps some political pressure from the Ministry, these things can be turned around."
However, Stiles said Waikato Hospital continued to generally be under enormous pressure.
He hoped that when similar problems are raised, they would get a similar level of priority and solutions from the highest levels.
"And I say when, not if."
Stiles had concerns about
outsourcing surgeries
to private hospitals being used as a long-term solution.
At present, Waikato cardiac patients are not having their surgeries outsourced because capacity within Waikato Hospital had been created.
"When I heard that there were these ideas to have 10-year contracts with private hospitals for surgical waitlists I thought, well that may be useful for the private hospitals but what the public hospitals really need is ability to turn the tap on and turn the tap off in private."
He said the risk became that public money would be used to build up private hospitals.
"I work in private, it's good, but I would much rather see public money go into a public hospital, I don't want to see public money propping up overseas pension funds who own private hospitals."
Sign up for Ngā Pitopito Kōrero
,
a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
26 minutes ago
- RNZ News
Private hospitals' use of publicly-funded cancer drugs will widen inequities, warn doctors
Under 'transitional access' private patients won't have to shift to the public system for 12 months. Photo: 123RF A move to allow private patients to access publicly-funded cancer drugs threatens to increase wait times for those in the public system, warn senior doctors. Under "transitional access", which comes into effect on 1 July, private patients who are already receiving treatment - or about to start treatment - with a newly funded medicine will not have to shift to the public system for 12 months. Associate Health Minister David Seymour, who has championed the rule change, said it would lessen stress on private patients by enabling continuity of care, and pressure on the public system which would no longer have to deal with a sudden influx of patients. However, the move has been criticised by opposition politicians as "a subsidy for private insurers", which already cover the cost of medicines newly funded by Pharmac, and of little benefit to patients. The Association of Salaried Medical Specialists, which represents 6500 senior hospital doctors and dentists, said its members working in oncology and haematology had "significant concerns" the change would widen inequities for patients. In a letter on June 13 to Pharmac's acting chief executive Brendan Boyle, the union's director of policy and research, Harriet Wild, quoted a briefing to the minister saying the policy change "would not increase volumes of cancer medicines provided in New Zealand, as only the location of treatments will change". "It will simply shift some of the existing capacity to the private system, where patients will need to fund infusion costs out-of-pocket," Wild wrote. "There will be pressure on the public system to ensure a smooth transition in treatment regime, which may mean delaying treatment for other people already waiting on the public list and unable to self-fund to start in private. "This potentially creates a two-tier waiting list and a system where those with more financial resources, will be prioritised for treatment." Furthermore, the shift of resources and inevitable increase in demand was likely to speed up the exodus of staff to the private sector, making public waiting lists even longer. A "back-pocket Q&A" provided to Seymour ahead of a Cabinet meeting on April 7 noted that the current eligibility criteria in the Pharmaceutical Schedule (excluding patients in private settings) was "designed to ensure public funding for medicines was prioritised for those managed in the public health system for cancer treatment, assessed by need, rather than public funding supporting those who chose to access treatment in private facilities. "Often the private treatment is funded from private health insurance that people have paid premiums into." In the same document, the minister said there was no plan to expand the policy to include other types of medicines or treatments "at this stage". "With that said, I've asked the Ministry [of Health] to do further work in this area to explore the possibility of broadening access to all publicly-funded medicines in private facilities - not just newly funded cancer medicines. "I encourage the private health providers and insurance companies to work closely with the ministry to support their understanding of how this might work in practice." Wild said opening access to publicly-funded drugs even wider would pull more staff away from the public system, reducing access for the majority who relied on it. "That would establish a system where a patient's ability to receive timely cancer care would depend on whether they could afford the out-of-pocket infusion costs." The government's 2024 Budget boost to Pharmac to widen access to medicines for patients had not been accompanied by extra resources for Te Whatu Ora to deliver the treatments, when public oncology services were already swamped with demand, Wild said. "Our members are increasingly needing to manage deteriorating patients, who are unable to access chemotherapy infusions in clinically acceptable timeframes. "This is unacceptable and represents a significant failure to invest in a planned and co-ordinated way to enable the public system to meet the needs of cancer patients, including those eligible for newly funded cancer medicines. "Whenever a new cancer drug is funded, it must be accompanied by an increase in the full package of care (staffing, infusion space, pharmacy) so that patients can actually receive the medicines within clinically acceptable timeframes." The Health Minister and David Seymour's office have been approached for comment. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
RNZ News
3 hours ago
- RNZ News
Psilocybin approved for depression
The government has announced the 'magic mushroom' drug psilocybin will become available for patients with treatment-resistant depression. Psychiatrist, Cameron Lacey, spoke to Ingrid Hipkiss. Tags: To embed this content on your own webpage, cut and paste the following: See terms of use.
RNZ News
4 hours ago
- RNZ News
Call for more medical access to commonly used illicit drugs
Prescription psilocybin, the hallucinogenic compound found in magic mushrooms, will become available to treat prescription-resistant depression. Photo: Pixabay The Drug Foundation wants more medical access to some of the most commonly used illicit drugs. It comes after the government announced prescription psilocybin , the hallucinogenic compound found in magic mushrooms, will become available to treat prescription-resistant depression. The Drug Foundation's annual report found psychedelic drug use has more than doubled in New Zealand, with 3.1 percent of adults reported taking psychedelics like LSD, psilocybin and ketamine in 2023 and 2024, compared to 1.3 percent in 2017 and 2018. It said cannabis, MDMA, and psychedelics rank down the lower end of the potential harm spectrum, and have well-documented medical uses. The Drug Foundation's executive director Sarah Helm said some people are self-medicating with such drugs, and are being criminalised by not being allowed to access them legally. "Many of our most popular illicit substances have well-documented medicinal uses and are being actively studied for their potential to treat a range of health conditions, so it's likely at least some of the use in this report is self-medication," Helm said. "We think it's time to enable more medical access to the likes of psychedelics and MDMA and stop prosecuting people who use them." In Australia, MDMA, known as ecstasy in tablet form, is being used to help treat post-traumatic stress disorder (PTSD). While earlier this year, a clinical study using mushrooms containing psilocybin to treat methamphetamine addiction completed its first phase of trials. "Criminalising anyone doesn't really help, whether the substance use is problematic or therapeutic," Helm told Morning Report. " Certainly, they [psychedelics] have been stigmatised and that's prevented access." NZ Drug Foundation executive director Sarah Helm. Photo: Supplied/ NZ Drug Foundation The release of these numbers coincides with Associate Health Minister David Seymour's announcement that psilocybin would be legally available in New Zealand outside of trials for the first time. It brings New Zealand in line with Australia, which has been using psilocybin to treat depression since 2023 . Seymour said it would initially only be available from one specific psychiatrist, but he hoped more would apply. The psychiatrist, Ōtautahi -based Dr Cameron Lacey, who was also behind the first clinical trials of psilocybin, said about two thirds of people who participated in clinical trials saw substantial improvements in their depression. "It's truly providing remarkable results and it's really exciting to see a treatment that is providing real benefit for people who typically, at that point in their treatment journey, had a really long road and low improvement from standard treatments," Dr Lacey told Morning Report. Dr Cameron Lacey. Photo: Supplied The therapy involves months of psychotherapy and one or two eight-hour psilocybin sessions or 'doses' accompanied by clinical professionals. Most of the studies have involved one or two doses integrated with a course of psychotherapy. For some, just one treatment can be sufficient . "The most important thing that we need to work on next is making sure this treatment is available to all who need it," Dr Lacy said. Helm said the announcement that the magic mushroom drug psilocybin will be available for some patients is good news, but better access is needed. "We do need to see a broader range of clinicians making it available, otherwise people do turn to self-administration. It's happens in the cannabis field, as well. It is about balancing," Helm said. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
